ABSTRACT
BACKGROUND: The incidence of dysnatremia in children with acute gastritis/gastroenteritis varies, and factors associated with either dysnatremia or hyponatremia at presentation have not been identified clearly. METHODS: This retrospective study included patients aged 1 month to 18 years hospitalized for community-acquired acute gastritis/gastroenteritis from January to October 2016. Factors associated with dysnatremia at presentation were identified using multivariable analysis. RESULTS: Among the 304 children included, the median age was 2.2 (1.0, 4.2) years. The incidence of dysnatremia at presentation was 17.1% (hyponatremia 15.8%; hypernatremia 1.3%). Patients who had moderate (p = 0.03) and severe dehydration (p = 0.04) and presented with vomiting and diarrhea simultaneously (p = 0.03) were associated with dysnatremia at presentation. Patients presented with vomiting and diarrhea simultaneously was associated with hyponatremia at presentation (p = 0.02). CONCLUSIONS: Dysnatremia was common in children with acute gastritis/gastroenteritis. Moderate to severe dehydration and the presence of vomiting and diarrhea simultanously were significantly associated with dysnatremia at presentation. Furthermore, presenting with vomiting and diarrhea silmutaneously was associated with hyponatremia at presentation. Serum electrolytes should be monitored in patients with those conditions.
Subject(s)
Dehydration , Gastritis , Gastroenteritis , Hypernatremia , Hyponatremia , Humans , Gastritis/epidemiology , Gastritis/complications , Gastritis/diagnosis , Male , Female , Retrospective Studies , Child, Preschool , Incidence , Infant , Hyponatremia/epidemiology , Hyponatremia/etiology , Child , Adolescent , Acute Disease , Gastroenteritis/complications , Gastroenteritis/epidemiology , Dehydration/epidemiology , Dehydration/etiology , Dehydration/complications , Hypernatremia/epidemiology , Hypernatremia/etiology , Hypernatremia/diagnosis , Hypernatremia/complications , Risk Factors , Diarrhea/epidemiology , Diarrhea/etiology , Vomiting/epidemiology , Vomiting/etiologyABSTRACT
Central diabetes insipidus (CDI) typically manifests as a polyuria-polydipsia syndrome, in which normonatremia is generally maintained through the polydipsia. A 53-year-old woman presented with diabetic ketosis and hyperosmolar hyperglycemic syndrome. Her medical history included herpes meningoencephalitis, which was associated with confusion and amnesia. On physical examination, she was apyretic, confused, and had signs of extracellular dehydration. Her capillary glucose concentration was high and her urine was positive for ketones. Laboratory investigations revealed severe hyperglycemia, hypernatremia (plasma hyperosmolarity of 393.6 mOsm/L), and mild acute renal failure. In addition, she had a paucisymptomatic COVID-19 infection. Intravenous rehydration with isotonic saline solution and insulin therapy were effective at controlling the ketosis and ameliorating the hyperglycemia, but failed to normalize the hypernatremia and hyperosmolarity. She was not thirsty and had a urine output of 1 L/day, with urinary hypotonicity. Desmopressin administration reduced the hypernatremia and hyperosmolarity to within their normal ranges, and the patient's urinary osmolarity increased to 743 mOsm/L. Therefore, adipsic CDI was diagnosed. Endocrine investigations revealed isolated central hypothyroidism. The results of pituitary magnetic resonance imaging were normal. Thus, patients with impaired thirst may have an atypical presentation of CDI. In addition, the diagnosis of adipsic CDI is particularly challenging.
Subject(s)
COVID-19 , Diabetes Insipidus, Neurogenic , Diabetes Insipidus , Diabetes Mellitus , Hyperglycemia , Hypernatremia , Meningoencephalitis , Humans , Female , Middle Aged , Diabetes Insipidus, Neurogenic/complications , Diabetes Insipidus, Neurogenic/drug therapy , Hypernatremia/complications , COVID-19/complications , PolydipsiaABSTRACT
BACKGROUND/AIM: The current study was designed to evaluate the etiologies of hypernatremic episodes in patients with severe burn injuries in comparison to critically ill non-burn patients. PATIENTS AND METHODS: The retrospective data acquisition was limited to the first 14 days and to patients with at least 20% total body surface area (TBSA) 2nd degree burn injuries or more than 10% TBSA when including areas of 3rd degree burn injuries. The results were compared to the results of a previously published study that analyzed the risk factors for hypernatremia in 390 non-burn intensive care unit patients. RESULTS: In total, 120 patients with a total of 50 hypernatremic episodes were included. Compared to non-burn injury patients, no significant differences were detectable except for a lower rate of hypokalemia and a higher rate of mechanical ventilation. The main trigger for hypernatremic episodes was the loss of free water, while 24% of the hypernatremic episodes seemed to be at least partly triggered by a surplus sodium influx. Patients with hypernatremic episodes had a significantly higher mortality rate. However, in none of the cases was hypernatremia the decisive cause of death. CONCLUSION: Besides the unique phenomenon of high volume internal and external volume shifts, the overall risk factors and etiologies of hypernatremia in patients with severe burn injury do not seem to significantly differ from other ICU patient collectives. Remarkably, a surplus of sodium influx and therefore a modifiable factor besides the specific burn injury volume resuscitation had an impact on the hypernatremic episodes in 24% of cases.
Subject(s)
Hypernatremia , Sodium , Humans , Hypernatremia/complications , Hypernatremia/epidemiology , Retrospective Studies , Intensive Care Units , Risk FactorsABSTRACT
Treatment of liver hydatid cysts is still in most cases surgical. To avoid the recurrence of hydatid cysts injection of scolicidal products inside the cystic cavity is an important step in the surgical procedure. Many scolicidal solutions are used. Hypertonic Saline Solution (HSS) is widely used by surgeons; however, there is a risk of hypertonic saline resorption and acute hypernatremia. Iatrogenic hypernatremia can be life-threatening. We report three cases of hypernatremia secondary to HSS injection for hydatid cyst disease treatment. The objective of this study was to discuss the clinical features, and treatment of this rare complication.
Subject(s)
Abdomen, Acute , Echinococcosis, Hepatic , Echinococcosis , Echinococcus , Hypernatremia , Animals , Humans , Hypernatremia/complications , Hypernatremia/drug therapy , Abdomen, Acute/complications , Abdomen, Acute/drug therapy , Echinococcosis/surgery , Echinococcosis, Hepatic/complications , Echinococcosis, Hepatic/surgery , Echinococcosis, Hepatic/drug therapy , Saline Solution, Hypertonic/therapeutic useABSTRACT
OBJECTIVES: To perform a detailed examination of sodium levels, hyponatremia and sodium fluctuations, and their association with delayed cerebral ischemia (DCI) and poor outcome after aneurysmal subarachnoid hemorrhage (aSAH). DESIGN: An observational cohort study from a prospective SAH Registry. SETTING: Tertiary referral center focused on SAH treatment in the Amsterdam metropolitan area. PATIENTS: A total of 964 adult patients with confirmed aSAH were included between 2011 and 2021. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 277 (29%) developed DCI. Hyponatremia occurred significantly more often in DCI patients compared with no-DCI patients (77% vs. 48%). Sodium levels, hyponatremia, hypernatremia, and sodium fluctuations did not predict DCI. However, higher sodium levels were significantly associated with poor outcome in DCI patients (DCI onset -7, DCI +0, +1, +2, +4, +5, +8, +9 d), and in no-DCI patients (postbleed day 6-10 and 12-14). Also, hypernatremia and greater sodium fluctuations were significantly associated with poor outcome in both DCI and no-DCI patients. CONCLUSIONS: Sodium levels, hyponatremia, and sodium fluctuations were not associated with the occurrence of DCI. However, higher sodium levels, hypernatremia, and greater sodium fluctuations were associated with poor outcome after aSAH irrespective of the presence of DCI. Therefore, sodium levels, even with mild changes in levels, warrant close attention.
Subject(s)
Brain Ischemia , Hypernatremia , Hyponatremia , Subarachnoid Hemorrhage , Adult , Humans , Subarachnoid Hemorrhage/complications , Prospective Studies , Sodium , Hypernatremia/complications , Hyponatremia/etiology , Brain Ischemia/complicationsSubject(s)
Hypernatremia , Myelinolysis, Central Pontine , Humans , Hypernatremia/complications , Hypernatremia/diagnosis , Hypernatremia/etiology , Myelinolysis, Central Pontine/diagnostic imaging , Myelinolysis, Central Pontine/etiology , Myelinolysis, Central Pontine/complications , Myelinolysis, Central Pontine/diagnosis , Male , Magnetic Resonance Imaging , Female , Severity of Illness Index , Middle AgedABSTRACT
STUDY OBJECTIVE: Hypernatremia is a treatable biochemical disorder associated with significant morbidity and mortality in patients undergoing surgery. However, its impact on patients who undergo elective craniotomy is not well understood. This study aimed to investigate the prognostic implications of postoperative hypernatremia on the 30-day mortality of patients undergoing elective craniotomy. DESIGN: Retrospective cohort study. SETTING: The Department of Neurosurgery of a high-volume center. PATIENTS: Adult patients undergoing elective craniotomy except those with pituitary tumors, intracerebral hemorrhage, subarachnoid hemorrhage, or traumatic brain injury. INTERVENTIONS: None. MEASUREMENTS: Perioperative laboratory data were collected for all study participants, including sodium levels, neutrophil count, serum albumin, lymphocyte count, and blood glucose. These measurements were obtained as part of routine clinical care and provided valuable information for data analysis. MAIN RESULTS: Of the 10,223 identified elective craniotomy patients who met our inclusion and exclusion criteria, 14.9% (1519) developed postoperative hypernatremia. This population's overall postoperative 30-day mortality rate was 1.7% (175). After performing an adjusted logistic regression analysis, we found that the odds of 30-day mortality increased gradually with increasing severity of hypernatremia: 2.9 deaths (OR, 3.79; 95% CI, 2.46-5.85) in patients with mild hypernatremia, 13.9 deaths (OR, 17.73; 95% CI, 11.17-28.12) in those with moderate hypernatremia, and 38.3 deaths (OR, 67.00; 95% CI, 40.44-111.00) in those with severe hypernatremia. CONCLUSIONS: Hypernatremia is common after elective craniotomy, and its presence is associated with increased mortality and complications, particularly in cases of severe hypernatremia. These results emphasize the significance of risk evaluation in neurosurgical patients and propose the advantages of closely monitoring serum sodium levels in high-risk individuals. Future randomized controlled trials could provide more insight into the effect of treating postoperative hypernatremia in these patients.
Subject(s)
Hypernatremia , Adult , Humans , Hypernatremia/complications , Hypernatremia/epidemiology , Retrospective Studies , Craniotomy/adverse effects , Prognosis , Sodium , Postoperative Complications/epidemiology , Postoperative Complications/etiologyABSTRACT
BACKGROUND: The COVID-19 pandemic worldwide has caused varying degrees of severity of lung damage in patients, with acute respiratory distress and death in severe cases. However, this is not directly caused by the virus itself, but by the production of inflammasome by monocytes in the body, leading to a systemic inflammatory response, which results in a very poor clinical prognosis for patients with COVID-19. OBJECTIVE: The purpose of this meta-analysis was to look at the relationship between hypernatremia and mortality in COVID-19 patients. METHODS: We searched the PubMed, Web of Science, Embase, and Cochrane databases for articles published from the inception of the database until August 27, 2022. Three researchers reviewed the literature, retrieved data, and assessed the quality of the literature, respectively. A meta-analysis was performed using State 17 software to assess the value of the effect of hypernatremia on mortality in patients with new coronavirus pneumonia. RESULTS: A total of nine publications was finally included in this study, including a total of 11,801 patients with COVID-19, including 1278 in the hypernatremia group and 10,523 in the normonatremia group. Meta-analysis showed that hypernatremia was associated with mortality in patients with COVID-19 [OR = 4.15, 95% CI (2.95-5.84), p = .002, I² = 66.7%] with a sensitivity of 0.36 [0.26, 0.48] and a specificity of 0.88 [0.83, 0.91]. The posterior probability of mortality was 42% in patients with COVID-19 hypernatremia and 15% in patients who did not have COVID-19 hypernatremia. CONCLUSION: According to available data, hypernatremia is associated with death in patients with COVID-19.
Subject(s)
COVID-19 , Hypernatremia , Humans , COVID-19/mortality , Hypernatremia/complications , Pandemics , PrognosisABSTRACT
O tratamento de desidratação e distúrbios eletrolíticos graves é contraindicado por meio de hipodermóclise, mas o nível de evidência da recomendação se baseia na opinião de especialistas. Descreve-se caso clínico de paciente com idade avançada, com indicação de cuidados paliativos, que evoluiu com desidratação hiperosmolar com hipernatremia grave, injúria renal aguda e hipercalemia. Tratou-se a paciente com solução hipotônica por meio da técnica de hipodermóclise, com resolução completa do quadro. Conclui-se que há necessidade de mais estudos sobre o uso da hipodermóclise para o tratamento de distúrbios hidroeletrolíticos graves.
The treatment of dehydration and severe electrolyte disturbances using hypodermoclysis is usually contraindicated, but the level of evidence for its recommendation is based on expert opinion. This case report describes an older patient receiving palliative care who developed hyperosmolar dehydration with severe hypernatremia, acute kidney injury, and hyperkalemia. She was treated with hypodermoclysis using a hypotonic solution, which led to complete resolution of the condition. In conclusion, further studies on the use of hypodermoclysis for the treatment of severe hydroelectrolytic disorders are needed.
Subject(s)
Humans , Female , Aged, 80 and over , Dehydration/complications , Hypodermoclysis/methods , Hyperkalemia/complications , Hypernatremia/complications , Palliative Care , Frail Elderly , Acute Kidney Injury/complications , Kidney/injuriesABSTRACT
Abstract Objective: To evaluate the association between dysnatremias or dyschloremias and mortality during hospitalization in patients with acute kidney injury (AKI) or chronic kidney disease (CKD) undergoing acute hemodialysis. Methods: We carried out a retrospective cohort study on adult patients undergoing acute hemodialysis with AKI or CKD diagnosis at a public hospital in Lima, Peru. Dysnatremias were categorized as hyponatremia (Na < 135mmol/L) or hypernatremia (Na > 145mmol/L), and dyschloremias were defined as hypochloremia (Cl < 98 mmol/L) or hyperchloremia (Cl > 109mmol/L). The outcome of interest was mortality during hospitalization. We performed generalized lineal Poisson family models with bias-corrected and accelerated non-parametric bootstrap to estimate the risk ratios at crude (RR) and adjusted analysis (aRR) by gender, age, HCO3 (for all patients) and Liaño score (only for AKI) with CI95%. Results: We included 263 patients (mean age: 54.3 years, females: 43%): 191 with CKD and 72 with AKI. Mortality was higher in patients with AKI (59.7%) than in patients with CKD (14.1%). In overall, patients with hypernatremia had a higher mortality during hospitalization compared to those who had normal sodium values (aRR: 1.82, 95% CI: 1.17-2.83); patients with hyponatremia did not have different mortality (aRR: 0.19, 95% CI: 0.69-2.04). We also found that hyperchloremia (aRR: 1.35, 95% CI: 0.83-2.18) or hypochloremia (aRR: 0.66, 95% CI: 0.30-14.78) did not increase mortality in comparison to normal chloride values. No association between dysnatremias or dyschloremias and mortality during hospitalization was found in CKD and AKI subgroups. Conclusions: In our exploratory analysis, only hypernatremia was associated with mortality during hospitalization among patients with AKI or CKD undergoing acute hemodialysis.
Resumo Objetivo: Avaliar a associação entre distúrbios do sódio ou do cloro e mortalidade hospitalar de pacientes com insuficiência renal aguda (IRA) ou doença renal crônica (DRC) submetidos a hemodiálise aguda. Métodos: O presente estudo de coorte retrospectiva incluiu pacientes adultos submetidos a hemodiálise aguda com diagnóstico de IRA ou DRC em um hospital público de Lima, Peru. Os distúrbios do sódio foram classificados como hiponatremia (Na < 135mmol/L) ou hipernatremia (Na > 145mmol/L), enquanto os distúrbios do cloro foram classificados como hipocloremia (Cl < 98 mmol/L) ou hipercloremia (Cl > 109mmol/L). O desfecho de interesse foi mortalidade hospitalar. Utilizamos modelos de Poisson da família de modelos lineares generalizados com bootstrap não-paramétrico e correção de viés acelerado para estimar os riscos relativos na análise bruta (RR) e ajustada (RRa) para sexo, idade, HCO3 (para todos os pacientes) e escore de Liaño (apenas para IRA) com IC 95%. Resultados: Foram incluídos 263 pacientes (idade média 54,3 anos; 43% do sexo feminino), 191 com DRC e 72 com IRA. A mortalidade foi mais elevada nos pacientes com IRA (59,7%) do que nos indivíduos com DRC (14,1%). No geral, os pacientes com hipernatremia tiveram mortalidade hospitalar mais elevada do que os indivíduos com valores normais de sódio (RRa: 1,82; IC 95%: 1,17-2,83). Os pacientes com hiponatremia não apresentaram mortalidade diferente (RRa: 0,19; IC 95%: 0,69-2,04). Também identificamos que hipercloremia (RRa: 1,35; IC 95%: 0,83-2,18) e hipocloremia (RRa: 0,66; IC 95%: 0,30-14,78) não elevaram a mortalidade em comparação a indivíduos com níveis normais de cloro. Não foi encontrada associação entre distúrbios do sódio ou do cloro e mortalidade hospitalar nos subgrupos com DRC e IRA. Conclusões: Em nossa análise exploratória, apenas hipernatremia apresentou associação com mortalidade hospitalar em pacientes com IRA ou DRC submetidos a hemodiálise aguda.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Sodium/blood , Chlorides/blood , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/mortality , Acute Kidney Injury/mortality , Peru/epidemiology , Bicarbonates/blood , Renal Insufficiency, Chronic/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/blood , Acute Kidney Injury/therapy , Hospitalization/statistics & numerical data , Hypernatremia/complications , Hypernatremia/mortality , Hyponatremia/complications , Hyponatremia/mortalityABSTRACT
Introducción: Las complicaciones neurológicas agudas durante la rehidratación intravenosa (RIV) de pacientes con deshidratación (DH) hipernatrémica se relacionan con el ritmo de descenso ocasionado en la osmolaridad efectiva plasmática (OEP) dependiente de la natremia, cuyas oscilaciones guardan una relación directa con la tonicidad y/o el ritmo de infusión (RI) de los fluidos empleados. Estos dos aspectos diferencian a las dos modalidades de RIV vigentes, la convencional (RIC) y la rápida (RIR). Una revisión exhaustiva de la experiencia publicada sobre RIR y dos análisis previos teóricos de ritmos máximos alcanzados en la RIC, así como del riesgo comparativo vinculado al ritmo de descenso natrémico en la RIC frente a la RIR, desde casos hipotéticos de DH hipernatrémica, permitieron identificar un tipo de solución (glucohidroelectrolítica isotónica-isoclorada [GHEITIC]) y un RI optimizados para proponer en el estudio. Objetivo: Evaluar la eficacia y la seguridad de la RIV de pacientes deshidratados hipernatrémicos con una solución GHEITIC (glucosa 4,7%, sodio 132,7 mmol/L, cloro109 mmol/L, acetato 42,8 mmol/L, potasio 19,4 mmol/L) en un RI genérico de 10 mL/kg/h (RIV-GHEITIC-10). Metodología: Estudio prospectivo y experimental de 62 pacientes (de 3 meses a 9 años de edad) deshidratados debido a pérdidas digestivas, tratados con RIV-GHEITIC-10; en 8 casos hipernatrémicos se analizó el curso clínico y analítico, cuya variable principal fue la natremia. Resultados: Las hipercloremias y las acidosis basales más intensas se concentraron significativamente en los casos hipernatrémicos y se corrigieron satisfactoriamente; el grado de DH basal había sido subestimado en todos los casos y presentaron con la RIV-GHEITIC-10 un descenso horario lento de la natremia (0,84 mmol/L/h), incluso incompleto en algunos, y todos terminaron la corrección por vía oral. No hubo ninguna hiponatremia final ni disionias significativas. Conclusiones: La RIV-GHEITIC-10 en casos de DH-hipernatrémica se demuestra eficaz, segura y fácil de ejecutar (AU)
Introduction: Acute neurological complications during intravenous rehydration (IVR) of patients with hypernatremic dehydration (DH) relate to the rate of resulted decline in effective plasmatic osmolality (EPO) dependent of natremia, whose oscillations are directly related to the tonicity and/or infusion rate (IR) of used fluids. These two aspects differentiate the two types of existing IVR guidelines: conventional (CIR) and rapid (RIR). A comprehensive review of published experience on RIR and two previous theoretical analysis of maximum rates achieved in CIR and comparative risk linked to the pace of natremic decline in CIR versus RIR from scenarios of hypernatremic-DH, identified both optimized type of solution (glucose hydro-electrolytic-isotonic-isoclhorinated [GHEITIC]) and IR to propose to study. Objective: To evaluate the efficacy and safety of IVR of hypernatremic dehydrated patients with a GHEITIC solution (glucose 4.7%, sodium 132.7 mmol/L, chlorine 109 mmol/L, acetate 42.8 mmol/L, potasium 19.4 mmol/L) at a generic IR of 10 mL/kg/h (GHEITIC-10-IVR). Methodology: A prospective, experimental study: on 8 hypernatremic cases of 62 dehydrated patients (3 months-9 years) by digestive losses, treated by GHEITIC-10-IVR, were analyzed their clinical and laboratory course; main variable: natremia. Results: Most intense basal hyperchloremias and acidosis significantly correspond with hypernatremic cases and were corrected satisfactorily; their basal DH degree had been underestimated in all and they presented during GHEITIC-10-IVR a slow decrease in natremia (0.84 mmol/L/h), even incomplete in some, but all ended the correction orally. There was no end hyponatremia or significant ionic disturbances. Conclusions: The GHEITIC-10-IVR of hypernatremic dehydrated cases proves to be effective, safe and easy to run (AU)
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Hypernatremia/complications , Dehydration/therapy , Fluid Therapy/methods , Brain Damage, Chronic/prevention & control , Patient Safety , Infusions, Intravenous , Rehydration Solutions/pharmacology , Isotonic Solutions/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Female , Aged, 80 and over , Myelinolysis, Central Pontine/blood , Myelinolysis, Central Pontine/complications , Myelinolysis, Central Pontine/diagnosis , Blood Glucose/analysis , Hyperglycemia/complications , Hyponatremia/complications , Hypernatremia/complications , Hypokalemia/diagnosis , Hypokalemia/therapy , Magnetic Resonance Spectroscopy/methods , Myelinolysis, Central Pontine/physiopathology , Osmolar ConcentrationABSTRACT
RESUMO Objetivo: Investigar os fatores clínicos e laboratoriais associados com a variação dos níveis séricos de sódio durante terapia renal substitutiva contínua e avaliar se a fórmula de mixagem perfeita pode prever a variação do sódio nas 24 horas. Métodos: A partir de uma base de dados coletada de forma prospectiva, recuperamos e analisamos os dados referentes a 36 sessões de terapia renal substitutiva realizadas em 33 pacientes, nas quais a prescrição de afluentes permaneceu inalterada durante as primeiras 24 horas. Aplicamos um modelo linear misto para investigar os fatores associados com grandes variações dos níveis séricos de sódio (≥ 8mEq/L) e geramos um gráfico de Bland-Altman para avaliar a concordância entre as variações previstas e observadas. Resultados: Nas sessões de terapia renal substitutiva de 24 horas identificamos que SAPS 3 (p = 0,022) e hipernatremia basal (p = 0,023) foram preditores estatisticamente significantes de variações séricas do sódio ≥ 8mEq/L na análise univariada, porém apenas hipernatremia demonstrou uma associação independente (β = 0,429; p < 0,001). A fórmula de mixagem perfeita para previsão do nível de sódio após 24 horas demonstrou baixa concordância com os valores observados. Conclusões: A presença de hipernatremia por ocasião do início da terapia renal substitutiva é um fator importante associado com variações clinicamente significativas dos níveis séricos de sódio. O uso de citrato 4% ou da fórmula A de ácido citrato dextrose 2,2% como anticoagulantes não se associou com variações mais acentuadas dos níveis séricos de sódio. Não foi viável desenvolver uma predição matemática da concentração do sódio após 24 horas.
ABSTRACT Objective: The aim of this study was to investigate the clinical and laboratorial factors associated with serum sodium variation during continuous renal replacement therapy and to assess whether the perfect admixture formula could predict 24-hour sodium variation. Methods: Thirty-six continuous renal replacement therapy sessions of 33 patients, in which the affluent prescription was unchanged during the first 24 hours, were retrieved from a prospective collected database and then analyzed. A mixed linear model was performed to investigate the factors associated with large serum sodium variations (≥ 8mEq/L), and a Bland-Altman plot was generated to assess the agreement between the predicted and observed variations. Results: In continuous renal replacement therapy 24-hour sessions, SAPS 3 (p = 0.022) and baseline hypernatremia (p = 0.023) were statistically significant predictors of serum sodium variations ≥ 8mEq/L in univariate analysis, but only hypernatremia demonstrated an independent association (β = 0.429, p < 0.001). The perfect admixture formula for sodium prediction at 24 hours demonstrated poor agreement with the observed values. Conclusions: Hypernatremia at the time of continuous renal replacement therapy initiation is an important factor associated with clinically significant serum sodium variation. The use of 4% citrate or acid citrate dextrose - formula A 2.2% as anticoagulants was not associated with higher serum sodium variations. A mathematical prediction for the serum sodium concentration after 24 hours was not feasible.
Subject(s)
Humans , Male , Female , Adult , Aged , Aged, 80 and over , Sodium/blood , Renal Replacement Therapy/methods , Hypernatremia/complications , Anticoagulants/administration & dosage , Linear Models , Prospective Studies , Databases, Factual , Citric Acid/administration & dosage , Glucose/administration & dosage , Glucose/analogs & derivatives , Hypernatremia/epidemiology , Middle AgedSubject(s)
Humans , Female , Aged, 80 and over , Hypernatremia/complications , Hypernatremia/diagnosis , Hypernatremia/drug therapy , Lithium/metabolism , Lithium/therapeutic use , Aphasia/complications , Aphasia/diagnosis , Aphasia/physiopathology , Aphasia/psychology , Language Arts , Language DevelopmentSubject(s)
Humans , Female , Middle Aged , Hypernatremia/complications , Hypernatremia/diagnosis , Hydrocephalus/complications , Hydrocephalus/diagnosis , Dehydration/complications , Hypopituitarism/complications , Hypopituitarism/diagnosis , Hypernatremia/physiopathology , Hypernatremia , Hydrocephalus , Osmolar Concentration , Urinary Tract Infections/complications , Urinary Tract Infections/therapy , Hydrocortisone/therapeutic use , Cerebral VentriclesABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Myelinolysis, Central Pontine/drug therapy , Myelinolysis, Central Pontine/surgery , Myelinolysis, Central Pontine/complications , Colectomy/methods , Hemofiltration/instrumentation , Hemofiltration/methods , Hemofiltration , Diuretics/therapeutic use , Hyponatremia/complications , Liver Transplantation/methods , Colonic Neoplasms/drug therapy , Colonic Neoplasms/surgery , Shock, Septic/complications , Shock, Septic/drug therapy , Hyperglycemia/complications , Hypernatremia/complications , Hypernatremia/diagnosisABSTRACT
Type 1 myotonic dystrophy (DM1) is an autosomal-dominant inherited disorder with a multisystem involvement, caused by an abnormal expansion of the CTG sequence of the dystrophic myotonia protein kinase (DMPK) gene. DM1 is a variable multisystem disorder with muscular and nonmuscular abnormalities. Increasingly, endocrine abnormalities, such as gonadal, pancreatic, and adrenal dysfunction are being reported. But, Electrolytes imbalance is a very rare condition in patients with DM1 yet. Herein we present a 42-yr-old Korean male of DM1 with abnormally elevated serum sodium and potassium. The patient had minimum volume of maximally concentrated urine without water loss. It was only cured by normal saline hydration. The cause of hypernatremia was considered by primary hypodipsia. Hyperkalemic conditions such as renal failure, pseudohyperkalemia, cortisol deficiency and hyperkalemic periodic paralysis were excluded. Further endocrine evaluation suggested selective hyperreninemic hypoaldosteronism as a cause of hyperkalemia.
Subject(s)
Adult , Humans , Male , Hyperkalemia/complications , Hypernatremia/complications , Hypoaldosteronism/complications , Kidney Concentrating Ability , Myotonic Dystrophy/complications , Potassium/blood , Protein Serine-Threonine Kinases/genetics , Sodium/bloodABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Hypernatremia/complications , Hypernatremia/diagnosis , Hypernatremia/drug therapy , Lithium/adverse effects , Lithium/therapeutic use , Bipolar Disorder/complications , Bipolar Disorder/drug therapy , Stroke/complications , Fluid Therapy , Hypernatremia/metabolism , Hypernatremia/physiopathology , Deamino Arginine Vasopressin/therapeutic use , Thiazides/therapeutic useABSTRACT
No disponible